Verfügbarkeit: Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life:

Gespeichert in:

Bibliographische Detailangaben
Beteilige Person:	Schulz, Thomas Ulrich (VerfasserIn)
Format:	Hochschulschrift/Dissertation Buch
Sprache:	Englisch
Veröffentlicht:	München 2024
Schlagwörter:	Krebs > Medizin Immuntherapie Therapie Hochschulschrift
Links:	https://doi.org/10.5282/edoc.33949 https://nbn-resolving.org/urn:nbn:de:bvb:19-339496
Umfang:	31 Blätter
DOI:	10.5282/edoc.33949

Internformat

MARC


LEADER	00000nam a2200000zc 4500
001	BV049821080
003	DE-604
005	00000000000000.0
007	t\|
008	240814s2024 gw m\|\|\| 00\|\|\| eng d
015			\|a 24,O09 \|2 dnb
035			\|a (OCoLC)1454743875
035			\|a (DE-599)BVBBV049821080
040			\|a DE-604 \|b ger
041	0		\|a eng
044			\|a gw \|c XA-DE-BY
049			\|a DE-384 \|a DE-473 \|a DE-703 \|a DE-1051 \|a DE-824 \|a DE-29 \|a DE-12 \|a DE-91 \|a DE-19 \|a DE-1049 \|a DE-92 \|a DE-739 \|a DE-898 \|a DE-355 \|a DE-706 \|a DE-20 \|a DE-1102 \|a DE-860 \|a DE-2174
084			\|8 2\p \|a 610 \|2 23sdnb
084			\|8 1\p \|a 616.994 \|2 23ksdnb
100	1		\|a Schulz, Thomas Ulrich \|e Verfasser \|0 (DE-588)1338316605 \|4 aut
245	1	0	\|a Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life \|c Thomas Ulrich Schulz
264		1	\|a München \|c 2024
300			\|a 31 Blätter
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
502			\|b Dissertation \|c München, Ludwig-Maximilians-Universität \|d 2024
583	1		\|a Archivierung/Langzeitarchivierung gewährleistet \|5 DE-101 \|2 pdager
650	0	7	\|8 3\p \|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|2 gnd
650	0	7	\|8 4\p \|a Immuntherapie \|0 (DE-588)4026640-0 \|2 gnd
650	0	7	\|8 5\p \|a Therapie \|0 (DE-588)4059798-2 \|2 gnd
655		7	\|0 (DE-588)4113937-9 \|a Hochschulschrift \|2 gnd-content
776	1	8	\|i Erscheint auch als \|n Online-Ausgabe \|o urn:nbn:de:bvb:19-339496 \|o 10.5282/edoc.33949
856	4	1	\|u https://doi.org/10.5282/edoc.33949 \|x Verlag \|z kostenfrei \|3 Volltext
856	4	1	\|u https://nbn-resolving.org/urn:nbn:de:bvb:19-339496 \|x Resolving-System \|z kostenfrei \|3 Volltext
912			\|a ebook
883	0		\|8 1\p \|a emakn \|c 1,00000 \|d 20240813 \|q DE-101 \|u https://d-nb.info/provenance/plan#emakn
883	0		\|8 2\p \|a emasg \|c 0,91533 \|d 20240813 \|q DE-101 \|u https://d-nb.info/provenance/plan#emasg
883	0		\|8 3\p \|a emagnd \|c 0,29148 \|d 20240813 \|q DE-101 \|u https://d-nb.info/provenance/plan#emagnd
883	0		\|8 4\p \|a emagnd \|c 0,12458 \|d 20240813 \|q DE-101 \|u https://d-nb.info/provenance/plan#emagnd
883	0		\|8 5\p \|a emagnd \|c 0,06121 \|d 20240813 \|q DE-101 \|u https://d-nb.info/provenance/plan#emagnd
943	1		\|a oai:aleph.bib-bvb.de:BVB01-035161273

Datensatz im Suchindex

DE-BY-TUM_katkey	2806324
_version_	1821937132244041728
any_adam_object
author	Schulz, Thomas Ulrich
author_GND	(DE-588)1338316605
author_facet	Schulz, Thomas Ulrich
author_role	aut
author_sort	Schulz, Thomas Ulrich
author_variant	t u s tu tus
building	Verbundindex
bvnumber	BV049821080
collection	ebook
ctrlnum	(OCoLC)1454743875 (DE-599)BVBBV049821080
doi_str_mv	10.5282/edoc.33949
format	Thesis Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02238nam a2200469zc 4500</leader><controlfield tag="001">BV049821080</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t\|</controlfield><controlfield tag="008">240814s2024 gw m\|\|\| 00\|\|\| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">24,O09</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1454743875</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049821080</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-2174</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">2\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">616.994</subfield><subfield code="2">23ksdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schulz, Thomas Ulrich</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1338316605</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life</subfield><subfield code="c">Thomas Ulrich Schulz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München</subfield><subfield code="c">2024</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">31 Blätter</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">München, Ludwig-Maximilians-Universität</subfield><subfield code="d">2024</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">Archivierung/Langzeitarchivierung gewährleistet</subfield><subfield code="5">DE-101</subfield><subfield code="2">pdager</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">3\p</subfield><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">4\p</subfield><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="8">5\p</subfield><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="776" ind1="1" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="o">urn:nbn:de:bvb:19-339496</subfield><subfield code="o">10.5282/edoc.33949</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.5282/edoc.33949</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:19-339496</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">emakn</subfield><subfield code="c">1,00000</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emakn</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">emasg</subfield><subfield code="c">0,91533</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emasg</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,29148</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">4\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,12458</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="883" ind1="0" ind2=" "><subfield code="8">5\p</subfield><subfield code="a">emagnd</subfield><subfield code="c">0,06121</subfield><subfield code="d">20240813</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#emagnd</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-035161273</subfield></datafield></record></collection>
genre	(DE-588)4113937-9 Hochschulschrift gnd-content
genre_facet	Hochschulschrift
id	DE-604.BV049821080
illustrated	Not Illustrated
indexdate	2024-12-20T20:22:50Z
institution	BVB
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-035161273
oclc_num	1454743875
open_access_boolean	1
owner	DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 DE-860 DE-2174
owner_facet	DE-384 DE-473 DE-BY-UBG DE-703 DE-1051 DE-824 DE-29 DE-12 DE-91 DE-BY-TUM DE-19 DE-BY-UBM DE-1049 DE-92 DE-739 DE-898 DE-BY-UBR DE-355 DE-BY-UBR DE-706 DE-20 DE-1102 DE-860 DE-2174
physical	31 Blätter
psigel	ebook
publishDate	2024
publishDateSearch	2024
publishDateSort	2024
record_format	marc
spellingShingle	Schulz, Thomas Ulrich Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life 3\p Krebs Medizin (DE-588)4073781-0 gnd 4\p Immuntherapie (DE-588)4026640-0 gnd 5\p Therapie (DE-588)4059798-2 gnd
subject_GND	(DE-588)4073781-0 (DE-588)4026640-0 (DE-588)4059798-2 (DE-588)4113937-9
title	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life
title_auth	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life
title_exact_search	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life
title_full	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz
title_fullStr	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz
title_full_unstemmed	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life Thomas Ulrich Schulz
title_short	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life
title_sort	persistent immune related adverse events after cessation of checkpoint inhibitor therapy prevalence and impact on patients health related quality of life
topic	3\p Krebs Medizin (DE-588)4073781-0 gnd 4\p Immuntherapie (DE-588)4026640-0 gnd 5\p Therapie (DE-588)4059798-2 gnd
topic_facet	Krebs Medizin Immuntherapie Therapie Hochschulschrift
url	https://doi.org/10.5282/edoc.33949 https://nbn-resolving.org/urn:nbn:de:bvb:19-339496
work_keys_str_mv	AT schulzthomasulrich persistentimmunerelatedadverseeventsaftercessationofcheckpointinhibitortherapyprevalenceandimpactonpatientshealthrelatedqualityoflife

Verfügbarkeit

Bestellen (Login erforderlich)

Online lesen (frei zugänglich)
Paper/Kapitel scannen lassen